arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

ANI PHARMACEUTICALS INC

ANIP
$78.35 ▼ -4.24 (-5.13%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
18 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
71
Health
Good
Bullish
auto_awesome

Analytical Summary

ANI PHARMACEUTICALS INC shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $1.6B
Dividend Yield
Revenue Growth 43.8%
Op. Margin 12.6%
ROIC 10.9%
FCF / Share $8.55
Trailing P/E 22.4x
Price / Book 3.3x
FCF Yield 10.9%
Debt / Equity 0.54
info Valuation on last close. End-of-day price, Aug 7, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$883.37M
↑ +43.8%
Net Income Profit after all expenses
$78.34M
↑ +522.9%
Operating Margin Operating profit as % of sales
12.6%
↑ +13130.2% 62th
FCF / Share Free cash flow per share
$8.55
↑ +245.6%
Long-Term Debt Long-term obligations
$291.84M
↓ -5.6%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
68
Returns
79
Financial Health
58
Cash Quality
88

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 67 quarters